NLRC5 and glioblastoma: Selective antigenic silencing is most evident in glioblastoma (GBM) hypermethylation or Polycomb occupancy at CIITA, NLRC5, TAP1/2, and HLA-A/B loci downregulates MHC-I/II expression without altering other immune programs (79, 80).